ZA202006324B - Lopinavir and ritonavir for the treatment of cervix disorders - Google Patents

Lopinavir and ritonavir for the treatment of cervix disorders

Info

Publication number
ZA202006324B
ZA202006324B ZA2020/06324A ZA202006324A ZA202006324B ZA 202006324 B ZA202006324 B ZA 202006324B ZA 2020/06324 A ZA2020/06324 A ZA 2020/06324A ZA 202006324 A ZA202006324 A ZA 202006324A ZA 202006324 B ZA202006324 B ZA 202006324B
Authority
ZA
South Africa
Prior art keywords
lopinavir
ritonavir
cervix
disorders
treatment
Prior art date
Application number
ZA2020/06324A
Other languages
English (en)
Inventor
Hampson Ian
Hampson Lynne
Original Assignee
Douglas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Douglas Pharmaceuticals Ltd filed Critical Douglas Pharmaceuticals Ltd
Publication of ZA202006324B publication Critical patent/ZA202006324B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2020/06324A 2018-05-24 2020-10-12 Lopinavir and ritonavir for the treatment of cervix disorders ZA202006324B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1808564.7A GB201808564D0 (en) 2018-05-24 2018-05-24 Treatments
PCT/IB2019/054292 WO2019224779A1 (en) 2018-05-24 2019-05-23 Lopinavir and ritonavir for the treatment of cervix disorders

Publications (1)

Publication Number Publication Date
ZA202006324B true ZA202006324B (en) 2022-01-26

Family

ID=62812406

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/06324A ZA202006324B (en) 2018-05-24 2020-10-12 Lopinavir and ritonavir for the treatment of cervix disorders

Country Status (12)

Country Link
US (2) US11738024B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801509A1 (cg-RX-API-DMAC7.html)
JP (1) JP7344911B2 (cg-RX-API-DMAC7.html)
CN (1) CN112203656B (cg-RX-API-DMAC7.html)
AU (1) AU2019274812B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020023964A2 (cg-RX-API-DMAC7.html)
CA (1) CA3100425A1 (cg-RX-API-DMAC7.html)
GB (1) GB201808564D0 (cg-RX-API-DMAC7.html)
MX (1) MX2020012656A (cg-RX-API-DMAC7.html)
SG (1) SG11202010138WA (cg-RX-API-DMAC7.html)
WO (1) WO2019224779A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006324B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) * 2019-11-27 2020-01-08 Pharmaceutic compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
ES2676151T3 (es) 2000-01-19 2018-07-17 Abbvie Inc. Formulaciones farmacéuticas mejoradas
US20020198160A1 (en) 2001-05-01 2002-12-26 Everitt Elizabeth A. Compositions and methods for enhancing the bioavailability of pharmaceutical agents
US20030129208A1 (en) 2002-01-07 2003-07-10 Alberts David S. Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses
US20040167139A1 (en) 2002-07-26 2004-08-26 Potter David A. Methods of treating cancer
BR0302523A (pt) 2003-07-23 2005-04-05 Cristalia Prod Quimicos Farm Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2582559A1 (en) 2003-11-28 2005-06-16 The University Of Manchester Treatment of hpv infections and cancer
US9005889B2 (en) 2007-01-16 2015-04-14 The Johns Hopkins University Synergistic antiviral compositions comprising a viral attachment inhibitor, integration inhibitor, and proviral transcription inhibitor
JP2011518184A (ja) 2008-04-18 2011-06-23 ナノバイオ コーポレーション ヘルペスウイルス感染の治療方法
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
KR20130139896A (ko) 2010-09-08 2013-12-23 프로노바 바이오파마 너지 에이에스 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물
GB201115635D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
CN102614114B (zh) 2012-04-26 2013-10-02 河南中医学院 一种维生素e自乳化软膏
WO2014143127A1 (en) 2013-03-15 2014-09-18 Differential Drug Development Associates Llc Emulsion formulations
WO2015059485A1 (en) * 2013-10-23 2015-04-30 The University Of Manchester Treatment of cancer and benign proliferative disorders
WO2016123541A2 (en) 2015-01-30 2016-08-04 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of encephalitis infection
WO2019130341A1 (en) 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201808567D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201808571D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) 2019-11-27 2020-01-08 Pharmaceutic compositions

Also Published As

Publication number Publication date
US20240148729A1 (en) 2024-05-09
AU2019274812A1 (en) 2020-12-10
WO2019224779A1 (en) 2019-11-28
GB201808564D0 (en) 2018-07-11
CN112203656B (zh) 2024-09-27
CA3100425A1 (en) 2019-11-28
SG11202010138WA (en) 2020-11-27
JP2021525266A (ja) 2021-09-24
US11738024B2 (en) 2023-08-29
US20210213015A1 (en) 2021-07-15
BR112020023964A2 (pt) 2021-02-23
JP7344911B2 (ja) 2023-09-14
US12678439B2 (en) 2026-07-14
EP3801509A1 (en) 2021-04-14
MX2020012656A (es) 2021-02-02
CN112203656A (zh) 2021-01-08
AU2019274812B2 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
DK4218640T3 (en) Systems for the treatment of disease states and disorders
IL288214A (en) Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders
ZA201906904B (en) Therapeutic agent for phosphodiesterase inhibition and its related disorders
IL271072A (en) Devices and methods for the treatment of body surface disorders
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
HUE059752T2 (hu) A danon betegség és az autofágia egyéb rendellenességeinek kezelésére szolgáló módszerek
IL279260A (en) KDM1A inhibitors for the treatment of diseases
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
SG11202010138WA (en) Lopinavir and ritonavir for the treatment of cervix disorders
IL276485A (en) Intrathecal epinephrine formulations and methods for treating the disease
PT3846754T (pt) Dispositivo para o tratamento de doenças do herpes
IL269400A (en) Medicines and preparations for the treatment of eye disorders
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL284032A (en) 3 beta-(benzyloxy)-17 alpha-methyl-paragan-5-en-20-one for use in the treatment of cognitive disorders
EP3371154A4 (en) Heterocyclic derivatives and their use in the treatment of central nervous system disorders
IL276697A (en) 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders
HK40052939A (en) Lopinavir and ritonavir for the treatment of cervix disorders
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
HK40028798A (en) Devices and methods for the treatment of body surface disorders
HK1260601A1 (en) Heterocycle derivatives and their use for the treatment of cns disorders
HK40023930A (en) Therapeutic agent for phosphodiesterase inhibition and its related disorders
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases